News
Check out the posts below to learn the latest updates on our progress
- November 11 2020EXUMA Biotech Presents Preclinical Data on Rapid Point-of-Care “rPOC” Subcutaneous CAR-T Platform at the SITC 35th Anniversary Annual Meeting & Pre-Conference
PR Newswire - November 9 2020Rapid point-of-care subcutaneous CAR-T from blood draw to injection in 4 hours with modified LV encoding CARs and synthetic driver elements enables efficient CAR-T expansion and tumor regression
SITC 35th Anniversary Annual Meeting & Pre-Conference (virtual) - October 19 2020Logic-gating HER2 CAR-T to the tumor microenvironment mitigates on-target, off-tumor toxicity without compromising cytotoxicity against HER2-over-expressing tumors
AACR Tumor Immunology & Immunotherapy 2020 - October 19 2020Dr. Sid Kerkar Joins EXUMA Biotech as Vice President Oncology, R&D, Company Presents Data on HER2-Targeting CAR-T at AACR Tumor Immunology and Immunotherapy ConferencePR Newswire
- October 7 2020Communicating Your Strategic Plan
CFO Thought Leader - September 24 2020Speeding the Delivery of CAR-T Therapies While Cutting the Cost
The BIO Report - August 10 2020Expanding Access to CAR-T: Dr. Greg Frost
PharmExec.com - August 3 2020How Big Data Is Accelerating EXUMA Biotech In The Race To Rapid CAR-T Therapy
BioProcess Online - June 16 2020EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of DirectorsPR Newswire
- May 12 2020Let’s Get the CAR-T Started
Longevity Technology